NCT02714569View on ClinicalTrials.gov

A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

February 15, 2017

Study Completion Date

February 15, 2017

Conditions
Dyslipidemias
Interventions
DRUG

LY3202328

Administered orally

DRUG

Placebo

Administered orally

DRUG

Atorvastatin

Administered orally

DRUG

Simvastatin

Administered orally

Trial Locations (4)

33014

Clinical Pharmacology of Miami, Inc., Miami

84106

PRA Health Sciences, Salt Lake City

06219

PRA Health Sciences, Lenexa

08053

PRA Health Sciences, Marlton

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02714569 - A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia | Biotech Hunter | Biotech Hunter